Show simple item record

dc.contributor.authorShah, Chintal H.
dc.contributor.authorDave, Chintan V.
dc.date.accessioned2023-11-03T17:15:14Z
dc.date.available2023-11-03T17:15:14Z
dc.date.issued2022-11-28
dc.identifier.urihttp://hdl.handle.net/10713/20999
dc.descriptionThe article processing charges (APC) for this open access article were partially funded by the Health Sciences and Human Services Library's Open Access Publishing Fund for Early-Career Researchers.en_US
dc.description.abstractBackground: There is paucity of data examining healthcare costs among persons with comorbid diabetes and cardiorenal conditions. Objective: To elucidate the longitudinal trends and quantify the incremental healthcare costs associated with the following cardiorenal conditions: atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and kidney disease, among persons with diabetes. Methods: Medical Expenditure Panel Survey data (2008–2019) were used to identify adults with diabetes and comorbid cardiorenal conditions. Overall, medical and pharmaceutical costs were ascertained (in 2019 US dollars). Analyses were adjusted for 14 variables using a two-part regression model. Results: Among 32,519 adults with diabetes, the mean (standard error [SE]) annual healthcare costs were $13,829 ($213), with medical and prescription components contributing $9301 ($172) and $4528 ($98), respectively. Overall healthcare costs rose by 26.8% from $12,791 (2008–2009) to $16,215 (2018–2019) over the study period, driven by 42.5% and 20.3% increase in pharmaceutical and medical spending, respectively. Similar trends were observed for subgroup of persons with cardiorenal conditions. Compared to their counterparts without cardiorenal conditions and prior to adjustment, persons with ASCVD, HF and kidney disease incurred healthcare costs that were approximately 2.2, 3.3, and 2.7 times greater. After adjustment, comorbid ASCVD, HF and kidney disease were associated with annual excess spending of $8651 (95% CI $7729–$9573), $9373 (95% CI $9010–$9736), and $9995 (95% CI $8781–$11,209), respectively. Conclusions: Study results are generalizable to non-institutionalized US persons. Healthcare costs associated with the management of diabetes are high—especially among those with comorbid cardiorenal conditions, and have risen in recent years.en_US
dc.language.isoen_USen_US
dc.relation.ispartofDiabetology & Metabolic Syndromeen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.lcshDiabetesen_US
dc.subject.meshHeart Failureen_US
dc.subject.meshKidney Diseasesen_US
dc.subject.meshCarotid Artery Diseasesen_US
dc.subject.meshCardio-Renal Syndromeen_US
dc.subject.meshHealth Care Costsen_US
dc.titleHealthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019en_US
dc.typeArticleen_US
refterms.dateFOA2023-11-03T17:15:17Z


Files in this item

Thumbnail
Name:
Shah_Chintal_APC_2022.pdf
Size:
781.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International